Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 14/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.40 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.40 |
| ▸ | UCHL5 | Q9Y5K5 | 1/20 | 0.39 |
| ▸ | KDR | P35968 | 1/20 | 0.38 |
| ▸ | TEK | Q02763 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25352125 | 0.92 | HDAC6 (0.45) | HDAC1HDAC6 | |
| SCHEMBL25993017 | 0.92 | KDM4E (0.52) | KDM4EHDAC1HDAC6HDAC3HDAC2 | |
| SCHEMBL24216545 | 0.92 | KDM4E (0.44) | KDM4EHDAC1HDAC6HDAC3HDAC2 | |
| SCHEMBL25352910 | 0.90 | HDAC6 (0.49) | KDM4EHDAC1HDAC6HDAC3HDAC2 | |
| SCHEMBL25352241 | 0.90 | HDAC1 (0.42) | KDM4EHDAC1HDAC6HDAC3HDAC2 | |
| SCHEMBL30409726 | 0.88 | UCHL5 (0.49) | HDAC1HDAC6HDAC3HDAC2HDAC10 | |
| SCHEMBL24215838 | 0.88 | UCHL5 (0.49) | HDAC1HDAC6HDAC3HDAC2HDAC10 | |
| SCHEMBL30408994 | 0.88 | HDAC1 (0.44) | HDAC1HDAC6HDAC3HDAC2HDAC10 | |
| SCHEMBL25349206 | 0.88 | HDAC1 (0.44) | HDAC1HDAC6HDAC3HDAC2HDAC10 | |
| SCHEMBL25350937 | 0.88 | HDAC6 (0.44) | HDAC1HDAC6HDAC3HDAC2HDAC10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230257372-A1 | NOVEL COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2023-08-17 | — | — | US | disclosed |
| US-20230257372-A1 | NOVEL COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2023-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230257372-A1 | NOVEL COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | HDAC6, HDAC1, HDAC3 | KDM4E 544/4885HDAC1 2/4885HDAC6 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.